Interim analysis from the phase III JAVELIN Bladder 100 trial suggest avelumab (Bavencio) as first-line maintenance in patients with urothelial cancer whose disease has not progressed with platinum-based chemotherapy should become the new standard or care, according to a late breaking abstract presentation at the 2020 ASCO Virtual Scientific Program.
In an interview with CancerNetwork, lead study author Thomas Powles, MD, PhD, director of Barts Cancer Centre, London, UK talked about future directions for avelumab research and treatment options for patients with advanced urothelial cancer as a whole.
Transcription:
So, there are two parts to that question. The first is are there next steps for the avelumab (Bavencio) program, and are there next steps for urothelial cancer more widely. And I think I’m going to answer the second question first, urothelial cancer is moving incredibly…
